Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 3
- Countries
- 0
Exclusivity
Patents and exclusivities
3| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10265265 | WYNZORAbetamethasone dipropionate; calcipotriene | product | Sept 2027 |
| 11696919 | WYNZORAbetamethasone dipropionate; calcipotriene | product | Mar 2039 |
| 12440499 | WYNZORAbetamethasone dipropionate; calcipotriene | product | Mar 2039 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Wynzora | Calcipotriene and Betamethasone dipropionate | cream, topical | 73499-001NDA |
Enquiry
Common questions
- Is MC2 Therapeutics Ltd FDA approved?
- MC2 Therapeutics Ltd holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does MC2 Therapeutics Ltd make?
- 1 product is listed under MC2 Therapeutics Ltd in the openFDA NDC Directory, most often as cream. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.